NICE says that in some exceptional circumstances the BMI requirements can drop down to 30, and people from some ethnic ...

The FDA is investigating two deaths in non-ambulatory Duchenne muscular dystrophy patients who received a Sarepta gene ...

By Chad Terhune LOS ANGELES (Reuters) -Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last ...

Danish pharma giant Novo Nordisk has brought its weight-loss drug Wegovy to India. This follows US company Eli Lilly's launch ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

Investing.com -- Novo Nordisk A/S (NYSE: NVO) stock dropped 2.1% premarket following news that Spain’s health ministry has requested clarification about the company’s obesity awareness campaign, which ...

Diabetes drug Ozempic and weight-loss jab Wegovy may also reduce the risk of dementia, according to a new study. American ...

With obesity and Type 2 diabetes on the rise, India is emerging as a key battleground for global drugmakers developing next-generation therapies targeting metabolic disorders.

Wegovy, a weekly weight-loss injection by Novo Nordisk, has launched in India. Priced from Rs 17,000/month, it helps users lose up to 20 per cent body weight. But is it safe? Experts answer.

Compounded weight loss drugs have been mostly off the market for about a month, but the weight loss drug industry remains as unsettled as ever.